Search results
Results from the WOW.Com Content Network
David H. Raulet is an American immunologist who specializes in studying the role of natural killer cells.He is a professor in the Department of Molecular and Cell Biology at the University of California, Berkeley where he also holds the Esther and Wendy Schekman Chair in cancer biology. [1]
For premium support please call: 800-290-4726 more ways to reach us
Axicabtagene ciloleucel (KTE-C19, ZUMA-3, YESCARTA) was an investigational therapy (for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL)) in which a patient's T cells were genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. [11]
Crowley left Genzyme to ensure that his children would qualify for a drug developed by the company. He then became founding president and CEO of Orexigen Therapeutics in 2003. In 2004, he became a director at Amicus Therapeutics, based in Cranbury, New Jersey, and in January 2005, he was named the president and CEO of the company. [17]
For premium support please call: 800-290-4726 more ways to reach us
Martin Shkreli (/ ˈ ʃ k r ɛ l i /; born March 17, 1983) is an American investor and businessman.Shkreli is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare, the co-founder and former CEO of pharmaceutical firms Retrophin and Turing Pharmaceuticals, and the former CEO of start-up software company Gödel Systems, which he founded in August 2016.
For premium support please call: 800-290-4726 more ways to reach us
Martine Aliana Rothblatt is an American lawyer, author, and entrepreneur. Rothblatt graduated from University of California, Los Angeles with J.D. and M.B.A. degrees in 1981, then began to work in Washington, D.C., first in the field of communications satellite law, then in bioethics and biomedicine. [3]